Aims: In this multicentre prospective registry we sought to evaluate the immediate and
midterm clinical outcomes following single or multiple overlapping bioresorbable vascular …

Aims: Early clinical results after implantation of bioresorbable vascular scaffolds (BVS) in ST-
elevation myocardial infarction (STEMI) are encouraging, but long-term data are missing …

Background—Bioresorbable vascular scaffolds (BVS) represent promising new technology,
but data on their long-term outcomes in ST-segment–elevation myocardial infarction …

Aims Recent studies have demonstrated favourable clinical outcomes for the everolimus-
eluting bioresorbable vascular scaffold (BVS) ABSORB™ in patients with stable coronary …

Abstract Aims Bioresorbable vascular scaffolds (BVSs) have been studied in chronic
coronary artery disease, but not in acute ST-segment elevation myocardial infarction …

Bioresorbable vascular scaffolds (BVS) represent a breakthrough technology for
percutaneous coronary intervention (PCI). In this context, because of the unique properties …

Aim: To evaluate 12-month clinical outcome, safety and effectiveness of BVS implantation in
complex lesions and in stable angina (SA) or ACS. Material and methods: Five hundred …

Objectives The aim of the study was to evaluate the healing process at 12 months after
ABSORB™ bioresorbable vascular scaffold (BVS) implantation in patients with ST‐segment …

Objectives To evaluate safety and efficacy of the everolimus-eluting bioresorbable scaffold
(BVS) in patients with ST-segment elevation myocardial infarction (STEMI). Background …

Aims We evaluated the feasibility and the acute performance of the everolimus-eluting
bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST …